Palvella Therapeutics, Inc. (PVLA) – What Are Investment Firms Saying About This Stock?

Palvella Therapeutics, Inc. (NASDAQ:PVLA) has been given a consensus recommendation of “Moderate Buy” by the sixteen research firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $209.79.

PVLA has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Friday, September 25th. Chardan Capital initiated coverage on Palvella Therapeutics in a research note on Monday, September 21st. They set a “buy” rating and a $240.00 price target on the stock. Raymond James Financial set a $226.00 price objective on Palvella Therapeutics in a research note on Friday. Truist Financial set a $207.00 price objective on Palvella Therapeutics in a research note on Wednesday, August 5th. Finally, William Blair started coverage on Palvella Therapeutics in a research note on Friday, October 16th. They set an “outperform” rating on the stock.

Palvella Therapeutics Stock Performance

NASDAQ PVLA opened at $123.92 on Wednesday. The stock’s fifty day moving average is $144.25 and its two-hundred day moving average is $134.51. The firm has a market capitalization of $1.79 billion, a P/E ratio of -25.66 and a beta of -0.27. Palvella Therapeutics has a fifty-two week low of $68.96 and a fifty-two week high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). As a group, sell-side analysts forecast that Palvella Therapeutics will post -6.41 EPS for the current year.

Insiders Place Their Bets

In other news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $152.24, for a total transaction of $654,936.48. Following the sale, the chief operating officer owned 2,154 shares of the company’s stock, valued at approximately $327,924.96. This trade represents a 66.64% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher P. Kiritsy sold 313 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $157.00, for a total transaction of $49,141.00. Following the sale, the director owned 250 shares of the company’s stock, valued at $39,250. This represents a 55.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 56,743 shares of company stock worth $8,219,632 in the last quarter. 17.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Palvella Therapeutics

A number of institutional investors have recently modified their holdings of PVLA. KBC Group NV purchased a new position in shares of Palvella Therapeutics in the 1st quarter worth $28,000. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Palvella Therapeutics in the second quarter valued at $35,000. Archer Investment Corp acquired a new position in Palvella Therapeutics in the 2nd quarter worth $69,000. Quantbot Technologies LP acquired a new position in Palvella Therapeutics in the 2nd quarter worth $71,000. Finally, State of Wyoming acquired a new position in Palvella Therapeutics in the 2nd quarter worth $134,000. 40.11% of the stock is owned by institutional investors and hedge funds.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing treatments for patients with serious rare diseases, including conditions that may have limited or no approved therapeutic options.

The company’s development programs are based on its QTORIN 3.0 technology platform, which is designed to deliver medicines locally through topical formulations. Palvella has applied the platform to investigational therapies for rare genetic skin disorders and other localized diseases, with the goal of improving treatment effectiveness while limiting systemic exposure.

Palvella is headquartered in Wayne, Pennsylvania, and conducts research and development activities aimed at serving rare-disease patients in the United States and other potential international markets.